<DOC>
	<DOCNO>NCT00895791</DOCNO>
	<brief_summary>The aim study compare vessel heal 9 month use OCT image two different treatment technique treat bifurcation lesion . Quantitative assessment OCT image use assess re-endothelialization quality strut apposition vessel wall .</brief_summary>
	<brief_title>COmplex BifuRcation Lesions : A Comparison Between AXXESS Device Culotte Stenting : An Optical Coherence Tomography ( OCT ) Study</brief_title>
	<detailed_description>Background : There ongoing controversy efficacy safety different bifurcation stenting technique . Critical consideration rate restenosis side branch ostium , completeness heal site overlap stent strut , may affect risk stent thrombosis . Methods : Patients complex bifurcation lesion involvement significant side branch require stent randomize two treatment arm . The first group 20 patient ( group I ) treat AXXESS Biolimus A9 Bifurcation Stent System ( Devax , Inc , Lake Forest CA ) , additional everolimus-eluting Xience V stent ( Abbott Vascular , Santa Clara , CA ) implant distal main branch side branch require . The second group 20 patient ( group II ) treat culotte technique use everolimus-eluting Xience V stent . Kissing balloon dilatation use non-compliant balloon complete index procedure case . At 9 month , control angiography ( QCA use dedicate software ) OCT ( main vessel side branch ) perform . Assessment Results : 1 . EP : stent strut coverage stent strut apposition , assess OCT 9 month . 2 . EP : restenosis , restenosis SB ostium , MACE , stent thrombosis .</detailed_description>
	<mesh_term>Coronary Stenosis</mesh_term>
	<criteria>1 . Patient old 18 year 2 . Written inform consent available 3 . Patient eligible percutaneous coronary intervention 4 . Patients de novo true coronary bifurcation lesion ( Medina classification ( 1,1,1 ) , ( 1,0,1 ) ( 0,1,1 ) ) 5 . Target reference vessel diameter measure QCA : 24 mm 6 . Target lesion stenosis measure QCA : &gt; 70 % &lt; 100 % 7 . Patients willing provide write informed consent prior participation willing able participate followup evaluation 1 . Left ventricular ejection fraction &lt; 30 % 2 . Impaired renal function ( serum creatinine &gt; 2.0 mg/dl ) 3 . Previous and/or plan brachytherapy target vessel 4 . Lesion leave main trunk &gt; 50 % , unprotected 5 . Known allergy antiplatelet , anticoagulation therapy , contrast medium everolimus 6 . Pregnant and/or breastfeed female female intend become pregnant ( pregnancy test require ) 7 . Patients life expectancy le one year 8 . Patient currently enrol investigational device drug trial 9 . Patient able willing adhere followup visit 10 . Patients intend major surgical intervention within 6 month enrolment study 11 . Patient able willing adhere followup visit 12 . Patients previously participate study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2009</verification_date>
	<keyword>coronary bifurcation</keyword>
	<keyword>stent implantation</keyword>
	<keyword>PCI</keyword>
	<keyword>Optical Coherence Tomography</keyword>
</DOC>